Mammalian target of rapamycin and its downstream signalling components are activated in psoriatic skin

British Journal of Dermatology

Volumn 169, Issue 1, 2013, Pages 156-159

  Buerger, C ^a   Malisiewicz, B ^a   Eiser, A ^a   Hardt, K ^a   Boehncke, W H ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN S6; S6 KINASE; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ARTICLE; BASEMENT MEMBRANE; CELL DIFFERENTIATION; CELL PROLIFERATION; EPIDERMIS; HUMAN; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; MOLECULE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PSORIASIS; SIGNAL TRANSDUCTION; SKIN BIOPSY; WESTERN BLOTTING; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY;

HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; PHOSPHORYLATION; PSORIASIS; RIBOSOMAL PROTEIN S6; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84879955291     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12271     Document Type: Article

References (15)

1. Laplante M, Sabatini DM,. mTOR signaling in growth control and disease. Cell 2012; 149: 274-93.
2. Chen SJ, Nakahara T, Takahara M, et al,. Activation of the mammalian target of rapamycin signalling pathway in epidermal tumours and its correlation with cyclin-dependent kinase 2. Br J Dermatol 2009; 160: 442-5.
3. Nestle FO, Kaplan DH, Barker J,. Psoriasis. N Engl J Med 2009; 361: 496-509.
4. Zhao J, Benakanakere MR, Hosur KB, et al,. Mammalian target of rapamycin (mTOR) regulates TLR3 induced cytokines in human oral keratinocytes. Mol Immunol 2010; 48: 294-304.
5. Young CN, Koepke JI, Terlecky LJ, et al,. Reactive oxygen species in tumor necrosis factor-alpha-activated primary human keratinocytes: implications for psoriasis and inflammatory skin disease. J Invest Dermatol 2008; 128: 2606-14.
6. Copp J, Manning G, Hunter T,. TORC-specific phosphorylation of mammalian target of rapamycin (mTOR): phospho-Ser2481 is a marker for intact mTOR signaling complex 2. Cancer Res 2009; 69: 1821-7.
7. Kjellerup RB, Iversen L, Kragballe K, Johansen C,. The expression and phosphorylation of eukaryotic initiation factor 4E are increased in lesional psoriatic skin. Br J Dermatol 2009; 161: 1059-66.
8. Bogenrieder T, Herlyn M,. The molecular pathology of cutaneous melanoma. Cancer Biomark 2011; 9: 267-86.
9. Chen S, Nakahara T, Uchi H, et al,. Immunohistochemical analysis of the mammalian target of rapamycin signalling pathway in extramammary Paget's disease. Br J Dermatol 2009; 161: 357-63.
10. Boehncke WH, Boehncke S, Schön MP,. Managing comorbid disease in patients with psoriasis. BMJ 2010; 340: b5666.
11. Boehncke WH, Boehncke S, Tobin AM, Kirby B,. The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 2011; 20: 303-7.
12. Buerger C, Richter B, Woth K, et al,. Interleukin-1β interferes with epidermal homeostasis through induction of insulin resistance: implications for psoriasis pathogenesis. J Invest Dermatol 2012; 132: 2206-14.
13. Ormerod AD, Shah SA, Copeland P, et al,. Treatment of psoriasis with topical sirolimus: preclinical development and a randomized, double-blind trial. Br J Dermatol 2005; 152: 758-64.
14. Reitamo S, Spuls P, Sassolas B, et al,. Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporin in the treatment of severe psoriasis: a randomized controlled trial. Br J Dermatol 2001; 145: 438-45.
15. Frigerio E, Colombo MD, Franchi C, et al,. Severe psoriasis treated with a new macrolide: everolimus. Br J Dermatol 2007; 156: 372-4.